SG11202101817UA - Methods of inhibition - Google Patents
Methods of inhibitionInfo
- Publication number
- SG11202101817UA SG11202101817UA SG11202101817UA SG11202101817UA SG11202101817UA SG 11202101817U A SG11202101817U A SG 11202101817UA SG 11202101817U A SG11202101817U A SG 11202101817UA SG 11202101817U A SG11202101817U A SG 11202101817UA SG 11202101817U A SG11202101817U A SG 11202101817UA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibition
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018903445A AU2018903445A0 (en) | 2018-09-13 | Methods of inhibition | |
| PCT/AU2019/050986 WO2020051648A1 (en) | 2018-09-13 | 2019-09-13 | Methods of inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101817UA true SG11202101817UA (en) | 2021-03-30 |
Family
ID=69776469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101817UA SG11202101817UA (en) | 2018-09-13 | 2019-09-13 | Methods of inhibition |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220047529A1 (de) |
| EP (1) | EP3849533A4 (de) |
| JP (1) | JP7457391B2 (de) |
| KR (1) | KR20210061355A (de) |
| CN (1) | CN112770734B (de) |
| AU (1) | AU2019338938B2 (de) |
| CA (1) | CA3111589C (de) |
| SG (1) | SG11202101817UA (de) |
| TW (1) | TW202023533A (de) |
| WO (1) | WO2020051648A1 (de) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095257A2 (en) * | 2013-12-18 | 2015-06-25 | Emory University | Managing visual dysfunction or loss of vision for diabetic subjects |
| US20160009705A1 (en) * | 2014-06-24 | 2016-01-14 | Sydnexis, Inc. | Ophthalmic composition |
| US10010502B2 (en) * | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
| WO2017060870A1 (en) * | 2015-10-09 | 2017-04-13 | Hermann Russ | Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease |
| KR102578476B1 (ko) * | 2016-04-11 | 2023-09-13 | 유니버시티 오브 캔버라 | 레보도파, 항산화제 및 수성 담체를 포함하는 안과 조성물 |
| US10155948B2 (en) * | 2016-05-12 | 2018-12-18 | Kangwon National University University-Industry Cooperation Foundation and | Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications |
-
2019
- 2019-09-13 US US17/276,082 patent/US20220047529A1/en active Pending
- 2019-09-13 JP JP2021513845A patent/JP7457391B2/ja active Active
- 2019-09-13 CN CN201980064834.XA patent/CN112770734B/zh active Active
- 2019-09-13 CA CA3111589A patent/CA3111589C/en active Active
- 2019-09-13 EP EP19860696.4A patent/EP3849533A4/de active Pending
- 2019-09-13 SG SG11202101817UA patent/SG11202101817UA/en unknown
- 2019-09-13 KR KR1020217009117A patent/KR20210061355A/ko unknown
- 2019-09-13 AU AU2019338938A patent/AU2019338938B2/en active Active
- 2019-09-13 WO PCT/AU2019/050986 patent/WO2020051648A1/en unknown
- 2019-09-16 TW TW108133177A patent/TW202023533A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022500405A (ja) | 2022-01-04 |
| EP3849533A4 (de) | 2022-06-22 |
| CA3111589A1 (en) | 2020-03-19 |
| CN112770734B (zh) | 2024-08-20 |
| KR20210061355A (ko) | 2021-05-27 |
| CN112770734A (zh) | 2021-05-07 |
| JP7457391B2 (ja) | 2024-03-28 |
| WO2020051648A1 (en) | 2020-03-19 |
| CA3111589C (en) | 2023-12-19 |
| TW202023533A (zh) | 2020-07-01 |
| US20220047529A1 (en) | 2022-02-17 |
| AU2019338938A1 (en) | 2021-03-18 |
| AU2019338938B2 (en) | 2023-01-19 |
| EP3849533A1 (de) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | kif18a inhibitors | |
| IL281939A (en) | VAP-1 inhibitors | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| GB201806072D0 (en) | Methods of manufacture | |
| EP3894768C0 (de) | Verfahren zur kryohärtung | |
| IL276592A (en) | History of Subtirum | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL281815A (en) | VAP-1 inhibitors | |
| ZA201904460B (en) | Inhibitors of nhe-mediated antiport | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| GB201805904D0 (en) | Methods of Manufacture | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
| IL276107A (en) | Crystalline forms of psoorstam | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL281409A (en) | Musk inhibition | |
| SG11202105136WA (en) | Application of chidamide | |
| SG11202101817UA (en) | Methods of inhibition | |
| AU2018903445A0 (en) | Methods of inhibition | |
| IL283421A (en) | Crystalline forms of Refroxlap | |
| GB201810835D0 (en) | Methods of use | |
| AU2018900997A0 (en) | Inhibition of ferroptosis | |
| GB201801181D0 (en) | Method of use | |
| PT3901141T (pt) | Nova forma de isoquinolinossulfonamida | |
| AU2017901956A0 (en) | Inhibition of ferroptosis |